COVINGTON, Ky. (Jan. 27, 2012) – Omnicare, Inc. (NYSE:OCR) today announced that it has extended its offer to purchase all outstanding shares of PharMerica Corporation (NYSE: PMC) common stock for $15.00 per share in cash to 5 p.m., New York City time, on Feb. 17, 2012, unless further extended. The tender offer was previously scheduled to expire at 5 p.m., New York City time, on Jan. 27, 2012. All other terms and conditions of the tender offer remain unchanged.
The depositary for the tender offer has advised that as of 5 p.m., New York City time, on Jan. 26, 2012, 4,710,805 shares of PharMerica common stock (including 600,661 shares subject to guarantees of delivery), representing approximately 16.0% of all outstanding shares, had been tendered into and not withdrawn from the tender offer.
The tender offer documents, including the Offer to Purchase, as amended, and the related Letter of Transmittal, have been filed with the Securities and Exchange Commission (“SEC”). The stockholders of PharMerica may obtain copies of the tender offer documents at www.sec.gov or by directing a request to D.F. King & Co., Inc., the Information Agent for the offer, by phone at (212) 269-5550 or toll-free at (800) 769-7666 or by email at [email protected]
Goldman, Sachs & Co. is acting as financial advisor to Omnicare and dealer manager for the offer and Dewey & LeBoeuf LLP and Axinn, Veltrop & Harkrider LLP are acting as legal counsel.
Omnicare, Inc., a Fortune 400 company based in Covington, Kentucky, provides comprehensive pharmaceutical services to patients and providers across North America. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care institutions, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry’s most innovative technological capabilities to the benefit of its long-term care customers. Omnicare also provides key commercialization services for the bio-pharmaceutical industry and end-of-life disease management through its Specialty Care Group. For more information, visit www.omnicare.com.